SimpleScreen CRC is indicated for adults 45 and up at average risk ...

The U.S. FDA has approved SimpleScreen CRC, a blood-based screening test for adults aged 45 years and older who are at ...

Freenome's newly approved blood test offers clinicians an alternative screening option for average-risk adults aged 45 and ...

Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and ...

Abbott will market Freenome’s SimpleScreen CRC test in the U.S., alongside its Cologuard stool test. SimpleScreen will ...

In July, the US Food and Drug Administration (FDA) approved a new blood-based test to screen for colorectal cancer (CRC). The FDA's approval of Shield (Guardant Health) marks a notable achievement, as ...

Developed by Freenome, the test is intended for adults aged 45 and older who are at average risk for CRC. It detects ...

The FDA has approved a second blood-based colorectal cancer screening option for adults aged 45 years and older at average ...

Freenome, an early cancer detection company developing blood-based screening tests, today announced favorable results from its pivotal clinical validation study assessing the performance of assay and ...

Abbott Laboratories (NYSE:ABT) has secured exclusive U.S. commercialization rights for Freenome's SimpleScreen CRC, a newly ...

Introduction Colorectal cancer (CRC) screening reduces cancer incidence and mortality, but participation rates are suboptimal ...

Although considered a single class, fecal immunochemical tests (FITs) vary in their ability to detect advanced colorectal neoplasia (ACN) and should not be considered interchangeable, new research ...